All In Biotech

Drug Trial Radar · NCT07004296

A Study of HDM2005 in Patients With Advanced Solid Tumor

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HDM2005 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Jul 1, 2027

Study completion Dec 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the efficacy, safety, and pharmacokinetics ofHDM2005 in participants with metastatic solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HDM2005Drug

    HDM2005 will be administered via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)Time frame: up to 21 days or 28 days following first dose
  2. Incident and severity of adverse events(for dose escalation phase)Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first.
  3. Progression-free survival(PFS)(for dose expansion phase)Time frame: Approximately 30 months
  4. Objective Response Rate (ORR)(for dose expansion phase)Time frame: Approximately 18 months
  5. Recommended Phase 2 Dose (RP2D) (for dose expansion phase) Recommended Phase 2 Dose (RP2D) (for dose expansion phase) Recommended Phase 2 Dose (RP2D) (for dose expansion phase)Time frame: Approximately 30 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.